{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T21:24:29Z","timestamp":1769203469482,"version":"3.49.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,10]],"date-time":"2022-02-10T00:00:00Z","timestamp":1644451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,5,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Ulipristal acetate (UPA) is a medical treatment for uterine fibroids and was authorized for surgical pre-treatment in 2012 after the conduct of the PEARL I and II randomized controlled trials and for intermittent treatment after the observational PEARL III and IV trials. However, UPA came into disrepute due to its temporary suspension in 2017 and 2020 because of an apparent association with liver injury. This clinical opinion paper aims to review the process of marketing authorization and implementation of UPA, in order to provide all involved stakeholders with recommendations for the introduction of future drugs. Before marketing authorization, the European Medicines Agency (EMA) states that Phase III registration trials should evaluate relevant outcomes in a representative population, while comparing to gold-standard treatment. This review shows that the representativeness of the study populations in all PEARL trials was limited, surgical outcomes were not evaluated and intermittent treatment was assessed without comparative groups. Implementation into clinical practice was extensive, with 900\u200a000 prescribed treatment cycles in 5 years in Europe and Canada combined. Extremely high costs are involved in developing and evaluating pre-marketing studies in new drugs, influencing trial design and relevance of chosen outcomes, thereby impeding clinical applicability. It is vitally important that the marketing implementation after authorization is regulated in such way that necessary evidence is generated before widespread prescription of a new drug. All stakeholders, from pharmaceutical companies to authorizing bodies, governmental funding bodies and medical professionals should be aware of their role and take responsibility for their part in this process.<\/jats:p>","DOI":"10.1093\/humrep\/deac009","type":"journal-article","created":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T20:06:27Z","timestamp":1641758787000},"page":"884-894","source":"Crossref","is-referenced-by-count":17,"title":["Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids"],"prefix":"10.1093","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0847-2566","authenticated-orcid":false,"given":"Mei-An","family":"Middelkoop","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E","family":"de Lange","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T Justin","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Birmingham Women\u2019s and Children\u2019s Hospital, Birmingham, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben Willem J","family":"Mol","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Monash University Monash Medical Centre, Clayton, Victoria, Australia"},{"name":"Department of Obstetrics and Gynaecology, Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK"},{"name":"Department of Obstetrics and Gynaecology, University of Aberdeen Aberdeen, Aberdeen, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre M","family":"Bet","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Pharmacy, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith A F","family":"Huirne","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wouter J K","family":"Hehenkamp","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,2,10]]},"reference":[{"key":"2022050519295692500_deac009-B1","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1067\/mob.2003.99","article-title":"High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence","volume":"188","author":"Baird","year":"2003","journal-title":"Am J Obstet Gynecol"},{"key":"2022050519295692500_deac009-B2","doi-asserted-by":"crossref","first-page":"e10926","DOI":"10.2196\/10926","article-title":"A patient registry for the management of uterine fibroids in Canada: protocol for a multicenter, prospective, noninterventional study","volume":"7","author":"Bedaiwy","year":"2018","journal-title":"JMIR Res Protoc"},{"key":"2022050519295692500_deac009-B3","author":"CADTH","year":"2017"},{"key":"2022050519295692500_deac009-B4","author":"CHMP","year":"2011"},{"key":"2022050519295692500_deac009-B5","author":"CHMP","year":"2015"},{"key":"2022050519295692500_deac009-B6","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/aogs.13713","article-title":"Ulipristal acetate vs gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): short-term results of a double-blind randomized controlled trial","volume":"99","author":"de Milliano","year":"2020","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2022050519295692500_deac009-B7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ejogrb.2020.06.035","article-title":"Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): long term results of a double-blind randomized controlled trial","volume":"252","author":"De Milliano","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022050519295692500_deac009-B8","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/humupd\/dmw023","article-title":"Uterine fibroid management: from the present to the future","volume":"22","author":"Donnez","year":"2016","journal-title":"Hum Reprod Update"},{"key":"2022050519295692500_deac009-B9","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.fertnstert.2015.09.032","article-title":"Long-term medical management of uterine fibroids with ulipristal acetate","volume":"105","author":"Donnez","year":"2016","journal-title":"Fertil Steril"},{"key":"2022050519295692500_deac009-B10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertil Steril"},{"key":"2022050519295692500_deac009-B11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal acetate versus placebo for fibroid treatment before surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"2022050519295692500_deac009-B12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal acetate versus leuprolide acetate for uterine fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"N Engl J Med"},{"key":"2022050519295692500_deac009-B13","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertil Steril"},{"key":"2022050519295692500_deac009-B14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejogrb.2010.05.012","article-title":"The burden of uterine fibroids in five European countries","volume":"152","author":"Downes","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022050519295692500_deac009-B15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2013.08.008","article-title":"The health disparities of uterine fibroid tumors for African American women: a public health issue","volume":"210","author":"Eltoukhi","year":"2014","journal-title":"Am J Obstet Gynecol"},{"key":"2022050519295692500_deac009-B16","author":"EMA","year":"2018"},{"key":"2022050519295692500_deac009-B17","author":"EMA","year":"2018"},{"key":"2022050519295692500_deac009-B18","author":"EMA","year":"2020"},{"key":"2022050519295692500_deac009-B19","author":"EMA","year":"2020"},{"key":"2022050519295692500_deac009-B20","author":"EMA","year":"2021"},{"key":"2022050519295692500_deac009-B21","author":"EMA"},{"key":"2022050519295692500_deac009-B22","author":"EMA","year":"2019"},{"key":"2022050519295692500_deac009-B23","author":"EMA","year":"2021"},{"key":"2022050519295692500_deac009-B24","author":"EMA","year":"2020"},{"key":"2022050519295692500_deac009-B25","author":"EMA","year":"2018"},{"key":"2022050519295692500_deac009-B26","author":"EMA","year":"2021"},{"key":"2022050519295692500_deac009-B27","author":"EMA","year":"2021"},{"key":"2022050519295692500_deac009-B28","author":"Euctr","year":"2014"},{"key":"2022050519295692500_deac009-B29","author":"European Commission","year":"2021"},{"key":"2022050519295692500_deac009-B30","doi-asserted-by":"crossref","first-page":"e0173523","DOI":"10.1371\/journal.pone.0173523","article-title":"Safety after extended repeated use of ulipristal acetate for uterine fibroids","volume":"12","author":"Fauser","year":"2017","journal-title":"PLoS One"},{"key":"2022050519295692500_deac009-B31","author":"FDA USFaDA","year":"2018"},{"key":"2022050519295692500_deac009-B32","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejogrb.2018.07.032","article-title":"Impact of uterine fibroids on quality of life: a national cross-sectional survey","volume":"229","author":"Herve","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022050519295692500_deac009-B33","author":"Higgins-Dun","year":"2021"},{"key":"2022050519295692500_deac009-B34","first-page":"CD000547","article-title":"Preoperative medical therapy before surgery for uterine fibroids","volume":"11","author":"Lethaby","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2022050519295692500_deac009-B35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1056\/NEJMoa1914735","article-title":"Uterine-artery embolization or myomectomy for uterine fibroids","volume":"383","author":"Manyonda","year":"2020","journal-title":"N Engl J Med"},{"key":"2022050519295692500_deac009-B36","author":"Medicine USNLo","year":"2021"},{"key":"2022050519295692500_deac009-B37","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1111\/bcp.14708","article-title":"Risk-efficacy balance of ulipristal acetate compared to surgical alternatives","volume":"87","author":"Middelkoop","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"2022050519295692500_deac009-B38","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejogrb.2020.10.058","article-title":"A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial","volume":"256","author":"Middelkoop","year":"2021","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2022050519295692500_deac009-B39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajog.2018.05.014","article-title":"Re: The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids","volume":"219","author":"Middelkoop","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"2022050519295692500_deac009-B40","author":"Netherlands C"},{"key":"2022050519295692500_deac009-B41","author":"PregLem","year":"2021"},{"key":"2022050519295692500_deac009-B42","author":"Richter","year":"2018"},{"key":"2022050519295692500_deac009-B43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ajog.2017.12.206","article-title":"The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids","volume":"218","author":"Singh","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"2022050519295692500_deac009-B44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/AOG.0b013e3181ed36b3","article-title":"Outcomes from leiomyoma therapies: comparison with normal controls","volume":"116","author":"Spies","year":"2010","journal-title":"Obstet Gynecol"},{"key":"2022050519295692500_deac009-B45","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/1471-0528.14640","article-title":"Epidemiology of uterine fibroids: a systematic review","volume":"124","author":"Stewart","year":"2017","journal-title":"BJOG"},{"key":"2022050519295692500_deac009-B46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1056\/NEJMe2017266","article-title":"Comparing apples to apples for fibroids","volume":"383","author":"Stewart","year":"2020","journal-title":"N Engl J Med"},{"key":"2022050519295692500_deac009-B47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(00)03622-9","article-title":"Uterine fibroids","volume":"357","author":"Stewart","year":"2001","journal-title":"Lancet"}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/5\/884\/43541455\/deac009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/humrep\/article-pdf\/37\/5\/884\/43541455\/deac009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T20:22:25Z","timestamp":1651782145000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/humrep\/article\/37\/5\/884\/6526433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,10]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2022,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deac009","relation":{},"ISSN":["0268-1161","1460-2350"],"issn-type":[{"value":"0268-1161","type":"print"},{"value":"1460-2350","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,2,10]]}}}